3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
63
Lymphoma, Mantle-Cell
39
Waldenstrom Macroglobulinemia
18
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Follicular
14
Recurrence
10
Lymphoma, B-Cell, Marginal Zone
10
Leukemia
9
Lymphoma, B-Cell
8
Lymphoma
8
Neoplasms
7
Lymphoma, Non-Hodgkin
5
Leukemia, Prolymphocytic
4
Hodgkin Disease
4
Multiple Myeloma
3
Leukemia, Myeloid, Acute
3
Leukemia, B-Cell
3
Hematologic Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Glioblastoma
2
Chromosome 17 deletion
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Bronchiolitis Obliterans Syndrome
2
Brain Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Prostatic Neoplasms
1
Primary Central Nervous System Lymphoma (PCNSL)
1
Interventions
Temozolomide
3
Irinotecan
3
Bevacizumab
3
Sorafenib
2
Radiosurgery
2
pembrolizumab
1
ibrutinib
1
Vorinostat
1
Valproic Acid
1
Transcranial Magnetic Stimulation
1
Therapeutics
1
Thalidomide
1
Surveys and Questionnaires
1
Standard of Care
1
Sildenafil Citrate
1
Radiotherapy
1
Palliative Care
1
Nivolumab
1
Morphine
1
Methadone
1
Lenalidomide
1
Laparoscopy
1
Equipment and Supplies
1
Eating
1
Cytidine Triphosphate
1
Bendamustine Hydrochloride
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neurologic Manifestations
×
ibrutinib
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled